Abstract: An intraocular lens for insertion into the capsular bag of an eye contains an optic, an outer periphery, and an outer support structure. The optic has a periphery and centered about an optical axis. The outer periphery is disposed about the optic and configured to engage an equatorial region of the capsular bag of an eye. The outer support structure is disposed along the periphery and spaced from the optic with voids outer support structure and the optic. The intraocular lens further comprises a first intermediate member and a weakened region disposed along the outer periphery between the outer support structure and the first intermediate member. The first intermediate member operably couples the optic and the outer support structure. The weakened region is attached to, and configured to provide relative motion between, the outer support structure and the first intermediate member in response to the ciliary muscle of the eye.

Abstract: An intraocular lens for insertion into the capsular bag of an eye contains an optic, an outer periphery, and an outer support structure. The optic has a periphery and centered about an optical axis. The outer periphery is disposed about the optic and configured to engage an equatorial region of the capsular bag of an eye. The outer support structure is disposed along the periphery and spaced from the optic with voids outer support structure and the optic. The intraocular lens further comprises a first intermediate member and a weakened region disposed along the outer periphery between the outer support structure and the first intermediate member. The first intermediate member operably couples the optic and the outer support structure. The weakened region is attached to, and configured to provide relative motion between, the outer support structure and the first intermediate member in response to the ciliary muscle of the eye.

Abstract: An intraocular lens for insertion into the capsular bag of an eye contains an optic, an outer periphery, and an outer support structure. The optic has a periphery and centered about an optical axis. The outer periphery is disposed about the optic and configured to engage an equatorial region of the capsular bag of an eye. The outer support structure is disposed along the periphery and spaced from the optic with voids outer support structure and the optic. The intraocular lens further comprises a first intermediate member and a weakened region disposed along the outer periphery between the outer support structure and the first intermediate member. The first intermediate member operably couples the optic and the outer support structure. The weakened region is attached to, and configured to provide relative motion between, the outer support structure and the first intermediate member in response to the ciliary muscle of the eye.

Abstract: The present invention addresses the treatment of ocular conditions by the enhancement of lens regeneration. Enhancement of lens regeneration is accomplished by the administration of a viscoelastic material in association with a composition comprising a polymer having functional acryl groups useful in the preparation of intraocular lenses (IOLs).

Abstract: A method for treating an ocular condition in a mammal includes removing an original lens to leave an empty lens capsule, filling the empty lens capsule with a gas to maintain capsule tension and prevent folding of the empty lens capsule, disposing a substance into said empty lens capsule that providing an internal scaffold for proliferation and differentiation of lens fibers; and selectively removing said substance by laser photoablation.

Abstract: The present invention addresses the treatment of ocular conditions by the enhancement of lens regeneration. This is accomplished by the administration of a high viscosity composition including a hyaluronic acid compound and laser photoablation. Excess high viscosity composition may be removed by focal laser photophacoablation. Additionally, a collagen product may be injected within the lens capsule to improve lens cell proliferation and differentiation, and to improve the configuration, shape and structure of regenerated lenses. Various embodiments involving the enhancement of lens regeneration are described. For example, lens regeneration may be enhanced by filling the lens capsule bag with the inventive hyaluronic acid compound; by inserting at least one collagen patch in the lens capsule; and/or by injecting a collagen-based product into the lens capsule.

Abstract: A method for the laser photoablation of ocular lens tissue comprises the steps of determining a volume of the lens tissue to be photoablated and directing a pulsed, infrared laser beam at the volume with an amount of energy effective for photoablating the determined region without causing substantial damage to surrounding tissue regions. The laser beam is initially directed at a focal point below an anterior surface of the ocular lens and such focal point is moved towards the ocular lens anterior surface in order to ablate the determined volume. The laser is preferably an Nd:YLF laser operating at a frequency of about 1053 nanometers and a pulse repetition rate of about 1000 Hertz with a pulse width of about 60 picoseconds. Each pulse has an energy of about 30 microjoules. The laser operates with a focused beam diameter of about 20 microns and operates with a “zone of effect” of no greater than about 50 microns.

Abstract: A method for the laser photoablation of ocular lens tissue comprises the steps of determining a volume of the lens tissue to be photoablated and directing a pulsed, infrared laser beam at the volume with an amount of energy effective for photoablating the determined region without causing substantial damage to surrounding tissue regions. The laser beam is initially directed at a focal point below an anterior surface of the ocular lens and such focal point is moved towards the ocular lens anterior surface in order to ablate the determined volume. The laser is preferably an Nd:YLF laser operating at a frequency of about 1053 nanometers and a pulse repetition rate of about 1000 Hertz with a pulse width of about 60 picoseconds. Each pulse has an energy of about 30 microjoules. The laser operates with a focused beam diameter of about 20 microns and operates with a “zone of effect” of no greater than about 50 microns.

Abstract: The present invention relates to methods to control undesired cell proliferation of remnant cells following surgery, by applying an effective amount of at least one proteoglycan-type substrate adhesion molecule (SAM) to the site of surgery. SAMs, in particular chondroitin sulfate, hyaluronic acid, and non-toxic, pharmaceutically acceptable salts thereof, alone or in a composition form, are typically used to prevent or inhibit growth of lens-related cells in a lens capsule after surgical removal of the lens, or to prevent proliferative vitreoretinopathy following retinal reattachment procedure performed with or without vitrectomy.

Abstract: A system for providing controlled release of an active agent in an eye includes a device with a shape thereof for enabling placement of the device under a conjunctiva of an eye and additionally preventing migration of the device in the eye after placement of the device under the conjunctiva. The device may be formed of a material permeable to the passage of an agent disposed in said device. In addition, a tracer may be incorporated in the device to enable visual indication of the amount of active agent in said device when said device is disposed under the conjunctiva. To selectively treat specific areas of the eye, an impermeable layer may be provided for preventing diffusion of the active agent from a selected area of the device.

Abstract: A system for providing controlled release of an active agent in an eye includes a device with a shape thereof for enabling placement of the device under a conjunctiva of an eye and additionally preventing migration of the device in the eye after placement of the device under the conjunctiva. The device may be formed of a material permeable to the passage of an agent disposed in said device. In addition, a tracer may be incorporated in the device to enable visual indication of the amount of active agent in said device when said device is disposed under the conjunctiva. To selectively treat specific areas of the eye, an impermeable layer may be provided for preventing diffusion of the active agent from a selected area of the device.

Abstract: Disclosed is a composition for preventing secondary cataract formation in the eye following removal of the lens, comprising an antibody specific to particular lens cells related to secondary cataract formation, which antibody is conjugated to an antiproliferative agent. The particularly preferred antiproliferative agents require activation after binding of the antibody to the target cells, and activation may be accomplished by addition of a second composition or by exposure of the eye to electromagnetic energy.Also disclosed is a method of using the composition by administering it directly to the site from which the lens was removed to kill or prevent proliferation of lens cells.